Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Announces Pricing of Initial Public Offering in the United States
October 16, 2020 11:20 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...
Opthea Announces Launch of Proposed Initial Public Offering in the United States
October 11, 2020 20:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 11, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea to Appoint Dr Jeremy Levin as Chairman of the Board
October 05, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Files Registration Statement for Proposed Initial Public Offering in the United States
September 25, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Appoints US-Based Non-Executive Director
September 10, 2020 12:04 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent...
Opthea Announces Plans to Conduct Registered Public Offering and Listing in the United States
August 24, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S....
Opthea Completes Successful Meetings with FDA and EMA for OPT-302 Phase 3 Clinical Program in Wet AMD
August 21, 2020 05:30 ET
|
Opthea Limited
Regulatory engagement provides clear pathway through Phase 3 to support filing for marketing approvals in US and EuropeRegulatory agreement of using Lucentis® and Eylea® in combination with OPT-302...
Opthea to Host Wet AMD and DME Key Opinion Leader Symposium on August 5, 2020 (EDT)
July 28, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, July 28, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Reports New Data of OPT-302 in Diabetic Macular Edema at the 2020 Annual Meeting of the American Society of Retina Specialists
July 27, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, July 27, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...